Synergy between low‐dose ranitidine and antacid in decreasing gastric and oesophageal acidity and relieving meal‐induced heartburn

Robinson, Malcolm; Rodriguez–Stanley, Sheila; Ciociola, Arthur A.; Filinto, Jonathan; Zubaidi, Sattar; Miner, Philip B.; Gardner, Jerry D.

doi:10.1046/j.1365-2036.2001.01058.x

Cited by 24 publications

(20 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the currently available therapeutic modalities are not fast or effective enough to provide good control of postprandial heartburn. [26][27][28][29][30] In patients who consume antireflux medications only in response to acute heartburn, PPIs appear to have no value due to the time required to reach maximum efficacy. Consequently, PPIs are not considered a good therapeutic option for postprandial heartburn, leaving patients to utilize compounds such as antacids, Gaviscon, sucralfate, or H2RAs.…”

Section: Postprandial Heartburnmentioning

confidence: 99%

Unmet Needs in the Treatment of Gastroesophageal Reflux Disease

Dickman

Maradey–Romero

Gingold‐Belfer

et al. 2015

J Neurogastroenterol Motil

View full text Add to dashboard Cite

Gastroesophageal reflux disease (GERD) is a highly prevalent gastrointestinal disorder. Proton pump inhibitors have profoundly revolutionized the treatment of GERD. However, several areas of unmet need persist despite marked improvements in the therapeutic management of GERD. These include the advanced grades of erosive esophagitis, nonerosive reflux disease, maintenance treatment of erosive esophagitis, refractory GERD, postprandial heartburn, atypical and extraesophageal manifestations of GERD, Barrett's esophagus, chronic protein pump inhibitor treatment, and post-bariatric surgery GERD. Consequently, any future development of novel therapeutic modalities for GERD (medical, endoscopic, or surgical), would likely focus on the aforementioned areas of unmet need.

show abstract

Section: Postprandial Heartburnmentioning

confidence: 99%

Unmet Needs in the Treatment of Gastroesophageal Reflux Disease

Dickman

Maradey–Romero

Gingold‐Belfer

et al. 2015

J Neurogastroenterol Motil

View full text Add to dashboard Cite

show abstract

“…The perception of heartburn serves as a trigger for medication use, and the expectation is an immediate symptom relief that PPIs are unlikely to provide. The onset of action of antacids on esophageal acid concentration is 30 min after dosing and inhibition persists for 1 h 65 . However, studies reported that meaningful heartburn relief can already be achieved 19 min after consumption 66 .…”

Section: Statementsmentioning

confidence: 99%

“…When consumed 30 min prior to a meal, H 2 RAs are effective in completely or partially preventing postprandial heartburn 68 . There is some evidence to suggest that simultaneous consumption of both an H 2 RA and an antacid provides better control of esophageal acid exposure and heartburn symptoms, when compared to the clinical effect of each one of these products alone 65 . On‐demand treatment with H 2 RAs has been shown to be safe and effective in GERD patients.…”

Section: Statementsmentioning

confidence: 99%

Asia‐Pacific consensus on the management of gastroesophageal reflux disease: Update

Fock

Talley

Fass

et al. 2007

J of Gastro and Hepatol

173

138

View full text Add to dashboard Cite

show abstract

“…Because cisapride had been reported previously to relieve heartburn, [11][12][13]16 we examined its effects on oesophageal and gastric pH and heartburn severity following a meal that has been found previously to induce heartburn in susceptible subjects. 25 The present report is based on results from a two-way crossover study of placebo and 10 mg cisapride administered with 65 mL of water 30 min before the start of the meal. This study was conducted during September and October 1998 -before cisapride was withdrawn for prescription use in humans.…”

Section: Methodsmentioning

confidence: 99%

Cisapride inhibits meal‐stimulated gastric acid secretion and post‐prandial gastric acidity in subjects with gastro‐oesophageal reflux disease

Gardner¹,

Rodriguez–Stanley

Robinson

et al. 2002

Aliment Pharmacol Ther

Self Cite

View full text Add to dashboard Cite

Summary Background and aims : KCNQ1 potassium channels in human gastric parietal cells are thought to be involved in gastric acid secretion. As cisapride can inhibit similar channels in other tissues and is an effective treatment for nocturnal heartburn, we examined the effects of cisapride on gastric and oesophageal acidity, gastric emptying and heartburn severity in subjects with gastro‐oesophageal reflux disease. Methods : Subjects (n=11) had suffered from heartburn four times or more per week for at least 6 months. Gastric pH and oesophageal pH were measured before, during and after a standard meal ingested over 15 min. Each subject received placebo or 10 mg cisapride orally, 30 min before the beginning of the meal. Meal‐stimulated gastric acid secretion was calculated from the amount of HCl required to titrate the homogenized standard meal to pH 2 in vitro and the time required for the pH of the ingested meal to decrease to pH 2 in vivo. Heartburn severity was assessed at 15‐min intervals beginning at the end of the meal. Gastric emptying of solids was measured using a [13C]‐octanoic acid breath test. Results : Cisapride significantly decreased meal‐stimulated gastric acid secretion by 20%, decreased integrated gastric and oesophageal acidity by 50–60% and transiently increased the expiration of 13CO2. Cisapride did not significantly alter heartburn severity. Conclusions : The cisapride‐induced decreases in meal‐stimulated gastric acid secretion, gastric acidity and oesophageal acidity in subjects with gastro‐oesophageal reflux disease can account for its beneficial clinical effects. These results also raise the possibility that gastric KCNQ1 potassium channels are important in meal‐stimulated gastric acid secretion and possibly in the pathophysiology of gastro‐oesophageal reflux disease.

show abstract

Synergy between low‐dose ranitidine and antacid in decreasing gastric and oesophageal acidity and relieving meal‐induced heartburn

Cited by 24 publications

References 48 publications

Unmet Needs in the Treatment of Gastroesophageal Reflux Disease

Unmet Needs in the Treatment of Gastroesophageal Reflux Disease

Asia‐Pacific consensus on the management of gastroesophageal reflux disease: Update

Cisapride inhibits meal‐stimulated gastric acid secretion and post‐prandial gastric acidity in subjects with gastro‐oesophageal reflux disease

Contact Info

Product

Resources

About